Chronic kidney disease. Chronic kidney disease (CKD)
Conditions
Interventions
The intervention group, patients are treated with empagliflozin tablets manufactured by Alhavi Pharmaceutical Company with a dose of 10 mg daily in the morning after breakfast. The medicine is deliver
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Patients over 18 years old Patients with 20=eGFR=75 mL/min/1.73m2 (calculated by MDRD formula) at the first visit
Exclusion criteria
Exclusion criteria: Dominant or autosomal recessive polycystic kidney disease, lupus nephritis or vasculitis with anti-neutrophil cytoplasmic antibody (ANCA) Received cytotoxic therapy, immunosuppressive therapy, or other immunologic therapy for primary or secondary renal disease within 6 months prior to the first visit Organ transplant history Blood pressure less than 90/60 mmHg Treatment with a sodium glucose cotransporter (SGLT 2) inhibitor within 8 weeks before the first visit or previous drug intolerance Frequent UTI Type 1 and 2 diabetes Class (NYHA) IV congestive heart failure at first visit Myocardial infarction, unstable angina, stroke and transient ischemic attack (TIA) within 12 weeks before the first visit Cardiovascular interventions such as CABG, PCI and valve replacement or repair within 12 weeks before the first visit Conditions such as malignancies where the patient does not have a good prognosis based on the clinical judgment of the researcher Active malignancy at the first visit Liver failure (AST and ALT more than three times normal and total bilirubin more than twice normal) Women prone to pregnancy who do not use contraceptive methods Pregnancy and breastfeeding Candida infection and low hygiene
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The reduction of microalbuminuria. Timepoint: The second, fourth and sixth months after starting the study. Method of measurement: Laboratory measurement of albumin to creatinine ratio in random urine samples.;Does the patient experience an increase in the ratio of albumin to creatinine in the random urine sample or not?. Timepoint: The second, fourth and sixth months after starting the study. Method of measurement: Laboratory measurement of albumin to creatinine ratio in random urine samples.;Checking the patient's GFR through the MDRD formula every two months. Timepoint: The second, fourth and sixth months after starting the study. Method of measurement: Laboratory measurement of serum creatinine and calculation of GFR through the MDRD formula. | — |
Secondary
| Measure | Time frame |
|---|---|
| The patient's condition in terms of high blood pressure and the use of antihypertensive drugs. Timepoint: The second, fourth and sixth months after starting the study. Method of measurement: Direct measurement of blood pressure.;Investigation of drug side effects such as urinary tract infection. Timepoint: The second, fourth and sixth months after starting the study. Method of measurement: Clinical interview. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactTahereh Sabaghian
Shahid Beheshti University of Medical Sciences
Outcome results
None listed